sterna biologicals GmbH & Co. KG
sterna biologicals GmbH & Co. KG is a clinical-stage immunology company developing first-in-class, safe and efficacious antisense oligonucleotide (ASO) based broad-spectrum immunomodulating therapies for millions of patients suffering from type 2 inflammation-driven diseases. The Company‘s proprietary DNAzyme-based drug candidate hgd40 has successfully proven its broad therapeutic potential in four Phase IIa clinical trials and sterna is now progressing hgd40 towards later-stage clinical development in the Company‘s lead indications of moderate to severe asthma and ulcerative colitis.
Sterna Biologicals at a glance:
|Field of Activity
||sterna’s proprietary DNAzyme hgd40 (a special type of antisense) is targeting GATA-3, a master transcription factor playing a central role in regulating Th2-driven inflammatory mechanisms, which allows the drug candidate to intervene with upstream inflammatory processes and address related diseases more effectively. In clinical trials, the Company has successfully demonstrated that GATA-3 downregulation could provide for a truly novel, broad-spectrum, non-steroidal anti-inflammatory therapy.|
|Ownership Structure and Financing||Privately held.|
|Products/Services||sterna’s lead programs in moderate to severe asthma (SB010) and ulcerative colitis (SB012) are both based on the Company‘s proprietary and patent protected active pharmaceutical ingredient hgd40 in different formulations.
SB010 in asthma: Inhaled liquid formulation of hgd40, has produced solid safety data and strong efficacy signals in mild asthmatics; enrolment of first patient in phase IIa proof-of-concept study with moderate to severe asthmatics is expected in Q4 2021.
SB012 in ulcerative colitis: Enema-based formulation has led to marked clinical and endoscopic improvements in phase IIa proof-of-principal trial with moderate to severe UC patients; sterna is developing an optimized formulation for further clinical development and commercialization.
sterna’s anti-inflammatory therapeutics pipeline also includes further GATA-3 antagonist development programs in COPD and atopic dermatitis.
|Unique selling point||While existing treatment options often only address one inflammatory mediator, by targeting GATA-3, hgd40 broadly antagonizes several inflammatory processes and mediators at the same time. With its DNAzyme hgd40, a unique antisense oligonucleotide (ASO) based approach, sterna is the only company that has successfully made GATA-3 druggable and demonstrated that GATA-3 downregulation could provide for a truly novel, game changing non-steroidal anti-inflammatory therapy.|
|Date of Incorporation/
Number of Employees
|Telephone/Telefax||+49 6421 98300-50/-599|